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ALAA	MOHAMMEDAHMED	ASHY		ABSTRACT			
Objective			The	main	objective	of	the	study	is	to	evaluate	the	effect	of	short-term	use	of	Phentermine	on	weight	loss	in	subjects	with	diabetes	compared	to	those	without.		
Study	Design	and	participants			This	retrospective	cohort	study	followed	a	group	of	individuals	with	obesity	in	a	non-surgical	weight	management	program	who	took	Phentermine	for	an	average	of	3	continuous	months.	Of	the	605	eligible	patients	who	have	started	taking	Phentermine	between	January	2015	and	June	2015,	285	patients	were	included	in	the	study.	Patients	taking	other	weight	loss	medications,	patients	with	missing	data	[height,	weight,	hemoglobin	A1c	(HbA1c)],	patients	lost	to	follow	up,	and	patients	under	the	age	of	21	or	over	65	were	excluded	from	the	study.		
	
Main	outcomes	and	measures			The	primary	outcome	is	percentage	weight	loss	after	an	average	of	3	months	of	continuous	use	of	Phentermine.	Clinical	variables	obtained	from	medical	records	included	HbA1c	level,	home	medications,	labs,	gender,	age,	first	date	of	Phentermine	prescription,	date	of	Phentermine	discontinuation,	and	weight	at	each	visit.		
		 vii 
	
Results		Most	participants	(91.58%)	lost	weight.	Among	those	with	a	normal	HbA1c	level	(HbA1c	<5.7)	(n=155),	89.68%	lost	weight,	while	93.33	%	of	pre-diabetics	(HbA1c	>=5.7	and	<6.5)	(n=90)	lost	weight,	and	92.5%	of	diabetics	(HbA1c	>=6.5)	(n=40)	lost	weight.	The	mean	%	weight	loss	for	all	participants	(n=285)	was	5.47%	(SD=4.39).	Those	without	diabetes	had	a	mean	%	weight	loss	of	5.59%	(SD=4.78);	pre-diabetics	lost	5.67%	(SD=4.17)	on	average	while	diabetics	lost	4.53	%(SD=3.06)	of	their	total	body	weight	(P-value	for	between	group	difference	in	percent	weight	loss=0.3413).	The	Bonferroni	post	hoc	test	also	indicated	that	there	was	no	significant	difference	in	%	weight	loss	between	groups.	
	
Conclusion		Diabetic	patients	had	a	lower	percentage	weight	loss	compared	to	those	with	no	diabetes	or	pre-diabetes	after	short-term	use	of	continuous	Phentermine.	However,	this	finding	did	not	provide	statistical	significance	between	the	groups.	Our	finding	also	provided	additional	insight	that	the	average	age,	months,	and	initial	BMI	between	the	groups	were	potential	confounders	in	our	study.	
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INTRODUCTION	Obesity	is	a	growing	epidemic	issue	worldwide.	In	the	United	States,	this	ubiquitous	disease	affects	approximately	35%	of	adults	leading	to	harmful	health	effects	such	as;	type	2	diabetes,	cardiovascular	disease,	stroke,	and	hypertension	(1).	Type	2	diabetes	is	associated	with	insulin	resistance,	while	weight	loss	is	known	to	enhance	insulin	sensitivity	(2).	Therefore,	the	high	prevalence	of	obesity	and	diabetes	and	their	severe	health	consequences,	warrant	the	development	of	pharmacotherapeutic	treatment	options	for	the	diseases	(3).		Phentermine	is	the	oldest	pharmacological	norepinephrine	releasing	agent	in	the	United	States	(4).	FDA	initially	approved	it	in	1959	for	short-term	treatment	of	obesity	(5).	Today,	it	is	the	most	commonly	prescribed	medication	to	treat	adults	who	are	overweight	with	comorbid	conditions	(BMI	of	≥25	kg/m2),	obese	(BMI	of	≥30	kg/m2),	or	morbidly	obese	(BMI	of	≥40	kg/m2)	(6)(7).			Phentermine	is	primarily	a	noradrenergic	and	perhaps	a	dopaminergic	sympathomimetic	amine	anorectic	(4).	Its	main	physiologic	function	is	appetite	suppression	(8).		Previous	clinical	trials	evaluated	the	effectiveness	of	Phentermine	in	combination	with	other	weight	loss	medications	for	obesity	treatment.	These	studies	provided	evidence	that	Phentermine	combination	therapy,	offers	synergistic	potential	for	weight	loss	effectiveness	with	mean	weight	loss	of	10%	and	weight	maintenance	for	up	to	2	years	(5).	Unlike	previous	studies,	this	study	will	focus	primarily	on	the	effectiveness	of	Phentermine	on	weight	reduction	without	other	weight	loss	medications	in	diabetic	
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patients,	and	the	main	outcome	is	%	weight	loss	in	each	group	(with	diabetes,	with	pre-diabetes,	without	diabetes).			Most	diabetic	patients	are	either	overweight	or	obese	with	increased	risk	of	hypertension	due	to	over	activity	of	sympathetic	nervous	system.	Phentermine	has	similar	effects	on	sympathomimetic	nerve	activity	and	it	can	be	associated	with	elevated	blood	pressure	and	pulse	rate	(9).	Therefore,	we	hypothesized	that	diabetic	patients	will	not	lose	as	much	weight	in	response	to	Phentermine	compared	to	the	other	groups.		
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METHODS	
		 This	retrospective	cohort	study	analyzed	non-surgical	weight	management	among	obese/overweight	participants	evaluated	by	weight	management	providers	at	Boston	Medical	Center	and	who	were	prescribed	and	took	Phentermine	as	an	isolated	weight	loss	drug	for	an	average	of	3	continuous	months.	Although	Phentermine	was	prescribed	to	all	eligible	participants,	some	patients	likely	discontinued	the	medication	due	to	its	side	effects.	Therefore,	patients	lost	to	follow	up	or	who	had	a	follow-up	period	of	less	than	2	months	were	excluded	from	the	study.		Because	height	and	body	fat	changes	with	aging,	those	who	were	below	21	and	over	65	years	old	were	also	not	included	in	the	study.	Therefore,	the	inclusion	criteria	consisted	of	adult	males	and	females	who	were	between	the	ages	of	21	and	65	years,	who	started	taking	Phentermine	between	January	2015	and	June	2015,	were	followed	up	for	an	average	of	3	continuous	months,	and	had	a	BMI	of	at	least	25.	 A	total	of	605	participants	started	taking	Phentermine	between	January	2015	and	June	2015;	195	were	excluded	from	the	study	due	to	taking	other	weight	loss	medications	such	as	Topirmate	(Topamax),	Lorcaserin,	Laltrexone,	Bupropion,	CONTRAVE	[bupropion	HCL+	naltrexone	HCL],	Qsymia	[Phentermine+Toparamate	extended	release	(ER)],	and	Orlistat.	Additionally,	89	patients	were	lost	to	follow	up,	21	had	missing	data	for	A1c,	height	or	weight	measurements,	and	15	were	out	of	the	
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specified	age	range.	The	final	sample	included	a	total	of	285	participants.	254	were	females	(89.1%)	and	31	were	males	(10.9%)	with	an	average	age	of	38.6(SD=10.4)	years.	Among	the	285	eligible	participants,	155	(54.39%)	had	normal	HbA1c	level	(HbA1c<	5.7),	90	(31.58%)	were	pre-diabetics	(5.7	>=HbA1c<6.5),	and	40	(14.04%)	were	diabetics	(HbA1c>=6.5)	as	shown	in	figure	1.			
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	Retrospective	Cohort	Study	Design.	
605	eligible	participants	
320	excluded:	
• 195	with	other	weight	loss	medication	
• 89	lost	to	follow	up	
• 21	missing	data	
• 15	age<21	or	>65	years	
285	total	participants	
155	No	Diabetes		 90	Pre-Diabetes	 40	Diabetes	
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The	American	Diabetes	Association	(ADA)	has	defined	that	the	diabetes	status	corresponds	to	the	following	HbA1C	levels:	normal	is	an	HbA1c	<	5.7,	pre-diabetes	is	an	HbA1c	>=5.7	and	<	6.5,	and	diabetes	is	an	HbA1c	>=6.5.	HbA1c	values	at	baseline	and	on	each	follow	up	visit	were	extracted	from	the	electronic	medical	record	of	Boston	Medical	Center.			Similarly,	height	and	weight	measurements	on	each	follow	up	visit	were	extracted	from	the	electronic	medical	record	of	Boston	Medical	Center.	The	weight	classification	corresponds	to	the	following	BMI	categories:	overweight	is	a	BMI	of	>=25	&	<30,	obese	is	a	BMI	of	>=	30	&	<	40,	and	morbidly	obese	is	a	BMI	of	>=	40.			STATISTICAL	ANALYSIS	All	statistical	analyses	were	performed	using	STATA	software.	A	one-way	ANOVA	(Analysis	of	Variance)	was	performed	to	test	if	any	of	the	three	groups	(No	diabetes,	Pre-diabetes,	Diabetes)	significantly	differ	from	each	other	in	one	or	more	characteristics.	The	analysis	was	performed	on	each	of	the	following	variables:	initial	weight	(kg),	initial	height	(inches),	initial	BMI,	age	in	years,	number	of	days	of	continuous	use	of	Phentermine,	final	weight	(kg),	final	BMI,	weight	change	per	month,	and	percentage	weight	loss.		Two	ANCOVA	(Analysis	of	Covariance)	analyses	were	also	performed	to	examine	the	influence	of	diabetes	status	on	%	weight	loss.	Model	1	adjusted	for	initial	BMI,	age	in	years,	gender,	and	number	of	months	of	continuous	use	of	Phentermine.	Model	2	included	only	females	and	adjusted	for	initial	BMI,	age	in	
	6 
years,	and	number	of	months	of	continuous	use	of	Phentermine.	Both	models	tested	whether	diabetes	status	possibly	influenced	%	weight	loss	after	adjusting	for	the	covariates	and	they	were	both	performed	only	for	adults	between	the	ages	of	21	and	65	and	who	were	taking	the	drug	for	an	average	of	3	continuous	months.			
Table	1.	Demographic	and	Health	Characteristics	of	adults	21-65	overall	and	
by	diabetes	status	
	 Overall	
n=285	
No	Diabetes	
n=155	
Pre-Diabetes	
n=90	
Diabetes	
n=40	
Age	(Years),	
Mean	(SD)	
38.63(10.28)	 36.10(9.14)a	 41.13(10.91)b	 42.82(11.16)b	
Age	(Min,	
Max)	
21.26-63.91	 21.26-63.38	 21.44-63.91	 21.30-62.42	
%	Females	 89.12	 93.55	 84.44	 82.50	
%	Males	 10.88	 6.45	 15.56	 17.50	
Days,	Mean	
(SD)	
90.19	(21.07)	 89.25	(21.16)a	 92.84	(21.35)a	 87.88	(20.02)a	
Initial	Height	
(inches),	Mean	
(SD)	
63.89	(3.19)	 63.85	(3.03)a	 63.80	(3.28)a	 64.19	(3.61)a	
Initial	Weight	
(kg),	Mean	
(SD)	
104.45	(20.50)	 101.91	(18.04)a	 104.48	(22.33)a	 114.18	(22.66)b	
Initial	BMI,	
Mean	(SD)	
39.59	(6.75)	 38.71	(5.98)a	 39.60	(6.83)a	 43.01(8.30)b	
Initial	
BMI>=25	&	<	
30	(%)	
4.56	 5.81	 4.44	 0	
Initial	
BMI>=30		&	<	
40	(%)	
52.28	 54.84	 54.44	 37.50	
Initial	BMI>=	
40	(%)	
43.16	 39.35	 41.11	 62.50	Note:	Means	with	common	subscripts	are	not	significantly	different	based	on	Bonferroni	post	hoc	test.		 			
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RESULTS		As	shown	in	table	1,	mean	initial	weight	varied	significantly	between	groups,	(P=0.0031).	Mean	baseline	weight	(114.2	kg)	of	subjects	with	diabetes	was	significantly	higher	than	those	of	subjects	with	pre-diabetes	(104.5	kg)	and	those	with	normal	HbA1c	levels	(101.9	kg).	The	baseline	weight	of	subjects	with	HbA1c	abnormalities	was	similar	to	that	of	subjects	with	pre-diabetes.	There	were	no	meaningful	differences	in	height	between	groups.	However,	the	initial	BMI	of	subjects	with	diabetes	(43.0	kg/m2,	SD=	8.30)	was	significantly	higher	than	that	of	subjects	with	neither	diabetes	or	pre-diabetes	(38.7	kg/m2,	SD=5.98).	Subjects	with	both	diabetes	and	pre-diabetes	were	somewhat	older	than	subjects	without.	Overall,	nearly	90%	of	subjects	in	this	analysis	were	females.	However,	there	were	a	somewhat	higher	proportion	of	males	among	those	with	diabetes	or	pre-diabetes.	Finally,	the	mean	number	of	days	of	continuous	use	of	Phentermine	was	not	significantly	different	between	groups	F(2,	282)=0.3310).	The	Bonferroni	post	hoc	test	also	indicated	that	there	was	no	significant	difference	in	the	mean	number	of	days	of	continuous	use	of	Phentermine	between	groups.					
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Table	2.	Weight	Change	status	and	Mean	percent	Weight	Loss	of	adults	21-65	
Overall	and	by	Diabetes	Status	
Weight	
Change	
Overall	
n=285	
No	Diabetes	
n=155	
Pre-Diabetes	
n=90	
Diabetes	
n=40	
Lost	Weight	
(%)	
91.58	 89.68	 93.33	 95.00	
Unchanged	
(%)	
0.35	 0.65	 0	 0	
Gained	
Weight	(%)	
8.07	 9.68	 6.67	 5.00	
%	Weight	
loss,	Mean	
(SD)	
5.47	(4.39)	 5.59	(4.78)a	 5.67	(4.17)a	 4.53	(3.06)a	
Note:	Means	with	common	subscripts	are	not	significantly	different	based	on	Bonferroni	post	hoc	test.	Weight	stayed	the	same	is	defined	as	0	kg	change	in	weight.			 As	shown	in	table	2,	most	participants	(91.58%)	lost	weight.	Among	those	with	a	normal	HbA1c	level	(HbA1c	<5.7)	(n=155),	89.68%	lost	weight,	while	93.33	%	of	pre-diabetics	(HbA1c	>=5.7	and	<6.5)	(n=90)	lost	weight,	and	92.5%	of	diabetics	(HbA1c	>=6.5)	(n=40)	lost	weight.	The	mean	%	weight	loss	for	all	participants	(n=285)	was	5.47%	(SD=4.39).	Those	without	diabetes	had	a	mean	%	weight	loss	of	5.59%	(SD=4.78);	pre-diabetics	lost	5.67%	(SD=4.17)	on	average	while	diabetics	lost	4.53	%(SD=3.06)	of	their	total	body	weight	(P-value	for	between	group	difference	in	percent	weight	loss=0.3413).	The	Bonferroni	post	hoc	test	also	indicated	that	there	was	no	significant	difference	in	%	weight	loss	between	groups.					
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Table	3.	Means	of	Final	BMI	after	Weight	Loss	of	Adults	21-65	Overall	and	by	
Diabetes	Status	
Final	Measures	 Overall	
n=285	
No	Diabetes	
n=155	
Pre-Diabetes	
n=90	
Diabetes	
n=40	
BMI	(kg/m2)	
	Mean	(SD)	
37.47	(6.85)	 36.59	(6.23)a	 37.40	(6.92)a	 41.04	(7.92)b	
Weight	
Change/Month	
(kg)	
Mean	(SD)	
1.92	(1.49)	 1.92	(1.52)a	 1.93	(1.44)a	 1.92(1.52)a	
25=<BMI	<	
30(%)	
10.99	 13.07	 11.24	 2.50	
30=<BMI<40(%)	 55.32	 56.21	 55.06	 52.50	
BMI>=40	(%)	 33.69	 30.72	 33.71	 45.00	Note:	Means	with	common	subscripts	are	not	significantly	different	based	on	Bonferroni	post	hoc	test.			
			
38.71	 39.6	
43.01	
36.59	 37.4	
41.04	
32	
34	
36	
38	
40	
42	
44	
Non-Diabetic	 Pre-Diabetic	 Diabetic	
Figure	2.	Initial	&	Final	Mean	BMI	by	Diabetes	Status	
(n=285)	
Initial		End	
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Figure	2	shows	the	initial	and	final	mean	BMI	by	diabetes	status	for	all	participants.	While	the	mean	initial	BMI	varied	between	groups	according	to	diabetes	status	and	mean	final	BMI	also	differed	between	groups	(p=0.011),	there	was	a	minor	difference	in	BMI	change	(from	baseline	to	final	BMI)	between	groups.	In	order	to	test	whether	the	final	BMI	also	varies	significantly	between	groups,	a	one-way	ANOVA	was	performed	and	the	mean	final	BMI	was	significantly	different	between	groups	F(2,	282)=0.0011	as	shown	in	Table	3.	The	Bonforroni	post	hoc	test	indicated	that	the	mean	final	BMI	of	diabetic	patients	(M=41.04,	SD=7.92)	was	significantly	different	from	pre-diabetic	(M=37.40,SD=6.92),	and	patients	with	no	diabetes	(M=36.59,	SD=6.23).		
	
	
	
	
4.51559	
4.91229	
4.38664	
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Figure	3.Mean	%	Weight	Loss	Adjusted	for	Age,	Sex,	
Initial	BMI,	&	Months	by	Diabetes	Status	
	11 
	The	ANCOVA	analysis	adjusted	for	initial	BMI,	age,	gender,	and	time	in	months	indicated	that	mean	%	weight	loss	in	diabetic	patients		(M=4.39,	SD=)	was	lower	than	pre	diabetic	(M=4.91,	SD=)	and	patients	with	no	diabetes	(M=4.52,	SD=0)	as	shown	in	figure	3.		The	regression	analysis	indicated	that	%	weight	loss	increased	by	0.40	%	in	pre-diabetic	and	decreased	by	0.13	%	in	diabetic	compared	to	patients	with	no	diabetes.	However,	this	result	was	not	statistically	significant.			
		 The	ANCOVA	analysis	performed	only	for	females	and	adjusted	for	initial	BMI,	age,	and	time	in	months,	showed	that	mean	%	weight	loss	in	diabetics		(M=5.26,	SD=0.78)	was	lower	than	pre	diabetics	(M=5.50,	SD=0.50)	and	patients	with	no	diabetes	(M=5.70,	SD=0.37)	as	shown	in	figure	4.	The	regression	analysis	
5.69656	
5.50196	
5.2568	
5	5.1	
5.2	5.3	
5.4	5.5	
5.6	5.7	
5.8	
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Figure	4.Females	Mean	%	Weight	Loss	Adjusted	for	
Initial	BMI,	Age,	&	Months	by	Diabetes	Status	
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indicated	that	%	weight	loss	decreased	by	0.195	%	in	pre-diabetics	and	by	0.440	%	in	diabetics	compared	to	patients	with	no	diabetes.	However,	this	result	was	not	statistically	significant	either		
Table	4.	Linear	regression	analysis	predicting	%	weight	loss	according	to	
diabetes	status	(n=285)		
%	Weight	Loss	 Coefficient	 P-value	 95%	Conf.	
Interval	
No	Diabetes	 Reference	 	 	
Pre-Diabetes	 0.40	 0.501	 −0.76						1.56	
Diabetes	 −0.13	 0.873	 −1.71						1.46	
Age	(Years)	 −0.05	 0.036	 −0.11			−	0.004	
Male	 Reference	 	 	
Female	 0.95	 0.252	 −0.68						2.57	
Time	(Months)	 1.10	 0.003	 			0.38						0.82	
Initial	BMI	 −0.10	 0.013	 −0.17				−0.02	Notes:	R2=0.0524			 Table	4	shows	the	results	of	the	regression	analysis	evaluating	predictors	of	percent	weight	loss.	The	diabetes	status	variables	were	not	statistically	significant	predictors	of	weight	loss	but	age,	duration	of	Phentermine	use,	and	initial	BMI	were.	For	each	additional	month	on	Phentermine,	there	was	a	1.1%	increase	in	percent	weight	loss.	In	contrast,	for	each	additional	1-unit	increase	in	initial	BMI,	there	was	a	0.10	decline	in	percent	weight	loss	(p=0.013).					
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Table	5.	Regression	analysis	result	for	females	alone	adjusted	for	age,	initial	
BMI,	and	time	(n=254)		
%	Weight	Loss	 Coefficient	 P-value	 95%	Conf.	
Interval	
No	Diabetes	 Reference	 	 	
Pre-Diabetes	 −0.20	 0.756	 −1.43						1.04	
Diabetes	 −0.44	 0.617	 −2.17						1.29	
Age	(Years)	 −0.05	 0.068	 −0.11						0.003	
Time	(Months)	 			1.24	 0.002	 −0.18				−0.0179	
Initial	BMI	 −0.10	 0.017	 3.26									2.50	Notes:	R2=0.0786	(P<0.05)			 Table	5	shows	the	results	of	the	regression	analysis	performed	for	females	alone	evaluating	predictors	of	percent	weight	loss.	Similarly,	the	diabetes	status	variables	were	not	statistically	significant	predictors	of	weight	loss	but	age,	duration	of	Phentermine	use,	and	initial	BMI	were.	For	each	additional	month	on	Phentermine,	there	was	a	1.24%	increase	in	percent	weight	loss.	In	contrast,	for	each	additional	1-unit	increase	in	initial	BMI,	there	was	a	0.10	decline	in	percent	weight	loss	(p=0.017).								
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DISCUSSION	
	Obesity	is	a	major	risk	factor	of	diabetes,	and	this	growing	epidemic	issue	has	been	fueled	with	major	increases	in	the	risk	of	hypertension,	hyperlipidemia,	cardiovascular	disease,	and	other	harmful	diseases.	Hypertension	is	twice	as	frequent	in	diabetics	due	to	over	activity	of	sympathetic	nervous	system,	and	studies	on	lifestyle	and	other	drug	therapies	have	shown	that	weight	loss	appears	to	be	even	more	difficult	in	diabetic	patients	(2).	On	the	other	hand,	previous	studies	have	also	found	that	weight	loss	can	enhance	insulin	sensitivity	and	improve	glucose	level	in	diabetic	patients	(10).	However,	a	number	of	factors	must	be	considered	when	treating	obese	diabetic	patients,	including	the	effect	of	the	treatment	on	weight.	Phentermine	is	the	oldest	FDA	approved	obesity	treatment	drug.	It	has	been	studied	in	combination	with	other	weight	loss	medications	in	obese	patients	for	weight	loss	effectiveness.	It	is	primarily	a	noradrenergic	and	perhaps	a	dopaminergic	sympathomimetic	amine	anorectic	(4).	The	main	physiologic	function	of	Phentermine	is	appetite	suppression	(8).	It	stimulates	the	release	of	norepinephrine	in	the	hypothalamus	and	reduces	hunger	(11).	Its	effectiveness	in	combination	with	other	weight	loss	medications	such	as	Topiramate	in	long-term	studies	was	found	to	achieve	an	average	of	5-10%	weight	loss.	(12)(13).	In	this	study,	however,	weight	loss	percentage	varied	widely	among	participants.	The	lowest	%	weight	loss	was	-4.98%	and	the	highest	was	18.85%.	That	is	to	say,	some	patients	have	gained	weight	and	some	have	not	lost	weight	indicating	that	Phentermine	effectiveness	varies	depending	on	pre-clinical	factors.		
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Unlike	previous	studies,	and	due	to	the	fact	that	we	have	examined	the	effect	of	short-term	use	of	Phentermine	on	weight	loss	in	combination	with	no	other	weight	loss	medications,	the	average	%	weight	loss	we	have	achieved	was	around	5	%.		 Sympathetic	nerve	over-activity	in	diabetic	patients	is	a	factor	in	the	pathogenesis	of	hypertension	(14).	Similarly,	studies	on	Phentermine	efficacy	showed	that	Phentermine	has	a	similar	sympathomimetic	effect	in	which	one	of	its	most	common	side	effects	is	increased	blood	pressure	(15).	Therefore,	considering	the	increased	activity	of	sympathetic	nervous	system	in	diabetic	patients,	we	hypothesized	that	diabetic	patients	would	have	a	lower	%	weight	loss	compared	to	patients	with	no	diabetes	or	pre-diabetes.	However,	our	analysis	did	not	corroborate	this.	Some	possible	explanations	for	this	include:	Patients	were	selected	based	on	Phentermine	starting	date	within	a	range	of	six	months	period	(January	2015-June	2015),	and	only	those	who	seemed	to	be	compliant	with	the	eligibility	criteria	were	included,	introducing	the	potential	for	selection	bias.		Moreover,	the	losses	to	follow	up	and	the	limited	number	of	diabetic	patients	who	were	included	in	the	study	could	have	interfered	with	our	result.	Only	40	(95%)	diabetic	patients	compared	to	217	patients	with	no	diabetes	or	pre-diabetes	among	the	257	patients	who	have	lost	weight	were	included	in	the	study.	The	study	also	could	not	take	into	consideration	the	confounding	effects	of	gender	in	a	meaningful	way,	as	the	number	of	males	was	very	small	in	our	sample,	and	it	was	difficult	to	accurately	compare	the	effect	of	the	drug	between	groups.	Another	
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limitation	is	the	absence	of	data	on	other	potential	confounding	factors.	Smoking	could	have	a	major	effect	on	body	weight.	It	can	increase	metabolic	rate,	decrease	metabolic	absorption,	reduce	appetite,	and	lead	to	weight	loss	(16).	Physical	activity	also	plays	an	important	role	in	weight	management	outcome.	Both	physical	activity	and	smoking	status	data,	which	are	major	variables	to	consider	in	weight	loss	studies,	were	not	available	for	this	study.	Additionally,	it	may	be	that	patients	who	have	achieved	meaningful	%	weight	loss	were	more	adherent	with	lifestyle	intervention,	confounding	the	interpretation	that	diabetic	patients	would	achieve	lower	%	weight	loss	than	patients	with	no	diabetes	or	pre-diabetes.	Finally,	the	conclusion	from	this	study	is	mainly	limited	by	the	small	study	sample	and	its	design	as	a	retrospective	cohort	study.		Because	it’s	a	retrospective	cohort	study,	we	relied	on	accurate	record	keeping	and	could	not	control	for	exposure	factors.	Therefore,	these	limitations	may	have	confounded	our	findings	and	may	also	partially	explain	the	insignificance	of	our	results.	However,	despite	the	limitations	of	the	study,	weight	loss	outcome	is	still	closely	correlated	with	pre-clinical	factors	and	varies	widely	among	individuals.		As	expected,	diabetic	patients	had	a	lower	percentage	weight	loss	compared	to	patients	with	no	diabetes	or	pre-diabetes	after	short-term	use	of	continuous	Phentermine,	and	it	may	be	that	the	%	weight	loss	achieved	in	this	study	could	approach	significance	between	the	groups	by	increasing	the	sample	size,	obtaining	physical	activity	and	smoking	status	records,	including	more	males,	and	possibly	including	a	placebo	group.		Finally,	it	may	be	more	appropriate	for	future	research	to	conduct	a	prospective	study	to	better	asses	the	
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correlation	between	diabetes	status	and	%	weight	loss	controlling	for	other	known	confounders.																				
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